Univariate analysis comparing ICH patients in the derivation cohort who survived or died within 30 days of ICH diagnosis
| . | Alive (n = 45) . | Dead (n = 25) . | P* . |
|---|---|---|---|
| Demographic features | |||
| Age, range, y | 29 (4-57) | 37 (12-54) | .038 |
| Male sex | 27 (60%) | 21 (84%) | .102 |
| Clinical features related to allo-HSCT | |||
| Primary disease† | .655 | ||
| AML | 13 (28.9%) | 7 (28.0%) | |
| ALL | 15 (33.3%) | 8 (32.0%) | |
| CML | 2 (4.4%) | 0 (0.0%) | |
| MDS | 6 (13.3%) | 6 (24.0%) | |
| AA | 5 (11.1%) | 1 (4.0%) | |
| Others | 4 (8.9%) | 3 (12.0%) | |
| Disease status | .022 | ||
| Standard risk | 38 (84.4%) | 15 (60.0%) | |
| High risk | 7 (15.6%) | 10 (40.0%) | |
| Time from diagnosis to HSCT, range, d | 227 (29-5992) | 208 (75-1750) | .637 |
| No. of transplantation | .091 | ||
| 1 | 44 (97.8%) | 22 (88.0%) | |
| 2 | 1 (2.2%) | 3 (12.0%) | |
| Type of transplantation | .031 | ||
| Haplo-identical | 40 (88.9%) | 17 (68.0%) | |
| HLA match | 5 (11.1%) | 8 (32.0%) | |
| Donor–patient sex | .611 | ||
| Match | 26 (57.8%) | 16 (64.0%) | |
| Mismatch | 19 (42.2%) | 9 (36.0%) | |
| ABO type | .372 | ||
| Match | 23 (51.1%) | 10 (40.0%) | |
| Mismatch | 22 (48.9%) | 15 (60.0%) | |
| Stem cell source | .463 | ||
| PB + BM | 39 (86.7%) | 20 (80.0%) | |
| PB | 6 (13.3%) | 5 (20.0%) | |
| WBC engraftment, range, d | 14 (10-22) | 14 (9-27) [n = 24] | .909 |
| Delayed PLT engraftment (> 30 d) | 22 (48.9%) | 12 (48.0%) | .943 |
| History of acute GVHD | .638 | ||
| None | 16 (35.6%) | 7 (28.0%) | |
| I-II | 22 (48.9%) | 12 (48.0%) | |
| III-IV | 7 (15.6%) | 6 (24.0%) | |
| History of chronic GVHD | .592 | ||
| None | 38 (84.4%) | 20 (80.0%) | |
| Limited | 1 (2.2%) | 0 (0.0%) | |
| Extensive | 6 (13.3%) | 5 (20.0%) | |
| History of TMA | 4 (8.9%) | 5 (20.0%) | .183 |
| History of DIC | 3 (6.7%) | 4 (16.0%) | .212 |
| Systemic infection | 35 (77.8%) | 20 (80.0%) | .828 |
| Clinical features related to ICH | |||
| Time from HSCT to ICH, range, d | 131 (14-1472) | 119 (21-944) | .686 |
| Bleeding site | .505 | ||
| IP | 27 (60.0%) | 18 (72.0%) | |
| SAH | 5 (11.1%) | 4 (16.0%) | |
| SD | 5 (11.1%) | 2 (8.0%) | |
| ED | 2 (4.4%) | 0 (0.0%) | |
| Multiple | 6 (13.3%) | 1 (4.0%) | |
| IVH | 4 (8.9%) | 6 (24.0%) | .083 |
| Preexisting CNS events‡ | 20 (44.4%) | 7 (28.0%) | .176 |
| Hypertension | 6 (13.3%) | 4 (16.0%) | .760 |
| Diabetes | 1 (2.2%) | 2 (8.0%) | .253 |
| Laboratory features | |||
| WBC count (×109/L) | 3.44 (1.31-14.11) | 2.11 (0.20-18.15) | .025 |
| RBC count (×1012/L) | 2.77 (1.57-4.53) | 2.28 (1.73-3.36) | .007 |
| Hemoglobin, g/dL | 90.20 (2.29-152.00) | 73.00 (63.00-113.00) | .008 |
| Platelet count (×109/L) | 55.0 (9.0-249.0) | 24.0 (2.0-74.0) | <.001 |
| PT, s | 11.80 (9.30-17.50) | 13.60 (10.00-20.20) | .045 |
| INR | 1.07 (0.87-1.54) | 1.22 (0.96-1.84) | .033 |
| Fibrinogen, mg/dL | 304.0 (101.0-550.0) | 319.0 (106.0-598.0) | .408 |
| LDH, U/L | 341.0 (155.0-1416.0) | 507.0 (118.0-1500.0) | .038 |
| Urea, mmol/L | 5.22 (1.12-21.12) | 7.78 (3.14-90.18) | .006 |
| Creatinine, µmol/L | 51.0 (21.0-137.0) | 70.0 (22.0-143.0) | .013 |
| Albumin, g/L | 36.5 (28.6-45.0) | 31.9 (21.3-47.1) | .001 |
| Bilirubin, µmol/L | 16.2 (2.0-341.1) | 40.6 (6.9-652.3) | .001 |
| Cholesterol, mmol/L | 4.49 (1.88-8.97) [n = 40] | 3.78 (1.14-16.44) [n = 24] | .560 |
| Triglyceride, mmol/L | 2.75 (1.29-9.89) [n = 40] | 2.50 (0.83-11.32) [n = 24] | .501 |
| . | Alive (n = 45) . | Dead (n = 25) . | P* . |
|---|---|---|---|
| Demographic features | |||
| Age, range, y | 29 (4-57) | 37 (12-54) | .038 |
| Male sex | 27 (60%) | 21 (84%) | .102 |
| Clinical features related to allo-HSCT | |||
| Primary disease† | .655 | ||
| AML | 13 (28.9%) | 7 (28.0%) | |
| ALL | 15 (33.3%) | 8 (32.0%) | |
| CML | 2 (4.4%) | 0 (0.0%) | |
| MDS | 6 (13.3%) | 6 (24.0%) | |
| AA | 5 (11.1%) | 1 (4.0%) | |
| Others | 4 (8.9%) | 3 (12.0%) | |
| Disease status | .022 | ||
| Standard risk | 38 (84.4%) | 15 (60.0%) | |
| High risk | 7 (15.6%) | 10 (40.0%) | |
| Time from diagnosis to HSCT, range, d | 227 (29-5992) | 208 (75-1750) | .637 |
| No. of transplantation | .091 | ||
| 1 | 44 (97.8%) | 22 (88.0%) | |
| 2 | 1 (2.2%) | 3 (12.0%) | |
| Type of transplantation | .031 | ||
| Haplo-identical | 40 (88.9%) | 17 (68.0%) | |
| HLA match | 5 (11.1%) | 8 (32.0%) | |
| Donor–patient sex | .611 | ||
| Match | 26 (57.8%) | 16 (64.0%) | |
| Mismatch | 19 (42.2%) | 9 (36.0%) | |
| ABO type | .372 | ||
| Match | 23 (51.1%) | 10 (40.0%) | |
| Mismatch | 22 (48.9%) | 15 (60.0%) | |
| Stem cell source | .463 | ||
| PB + BM | 39 (86.7%) | 20 (80.0%) | |
| PB | 6 (13.3%) | 5 (20.0%) | |
| WBC engraftment, range, d | 14 (10-22) | 14 (9-27) [n = 24] | .909 |
| Delayed PLT engraftment (> 30 d) | 22 (48.9%) | 12 (48.0%) | .943 |
| History of acute GVHD | .638 | ||
| None | 16 (35.6%) | 7 (28.0%) | |
| I-II | 22 (48.9%) | 12 (48.0%) | |
| III-IV | 7 (15.6%) | 6 (24.0%) | |
| History of chronic GVHD | .592 | ||
| None | 38 (84.4%) | 20 (80.0%) | |
| Limited | 1 (2.2%) | 0 (0.0%) | |
| Extensive | 6 (13.3%) | 5 (20.0%) | |
| History of TMA | 4 (8.9%) | 5 (20.0%) | .183 |
| History of DIC | 3 (6.7%) | 4 (16.0%) | .212 |
| Systemic infection | 35 (77.8%) | 20 (80.0%) | .828 |
| Clinical features related to ICH | |||
| Time from HSCT to ICH, range, d | 131 (14-1472) | 119 (21-944) | .686 |
| Bleeding site | .505 | ||
| IP | 27 (60.0%) | 18 (72.0%) | |
| SAH | 5 (11.1%) | 4 (16.0%) | |
| SD | 5 (11.1%) | 2 (8.0%) | |
| ED | 2 (4.4%) | 0 (0.0%) | |
| Multiple | 6 (13.3%) | 1 (4.0%) | |
| IVH | 4 (8.9%) | 6 (24.0%) | .083 |
| Preexisting CNS events‡ | 20 (44.4%) | 7 (28.0%) | .176 |
| Hypertension | 6 (13.3%) | 4 (16.0%) | .760 |
| Diabetes | 1 (2.2%) | 2 (8.0%) | .253 |
| Laboratory features | |||
| WBC count (×109/L) | 3.44 (1.31-14.11) | 2.11 (0.20-18.15) | .025 |
| RBC count (×1012/L) | 2.77 (1.57-4.53) | 2.28 (1.73-3.36) | .007 |
| Hemoglobin, g/dL | 90.20 (2.29-152.00) | 73.00 (63.00-113.00) | .008 |
| Platelet count (×109/L) | 55.0 (9.0-249.0) | 24.0 (2.0-74.0) | <.001 |
| PT, s | 11.80 (9.30-17.50) | 13.60 (10.00-20.20) | .045 |
| INR | 1.07 (0.87-1.54) | 1.22 (0.96-1.84) | .033 |
| Fibrinogen, mg/dL | 304.0 (101.0-550.0) | 319.0 (106.0-598.0) | .408 |
| LDH, U/L | 341.0 (155.0-1416.0) | 507.0 (118.0-1500.0) | .038 |
| Urea, mmol/L | 5.22 (1.12-21.12) | 7.78 (3.14-90.18) | .006 |
| Creatinine, µmol/L | 51.0 (21.0-137.0) | 70.0 (22.0-143.0) | .013 |
| Albumin, g/L | 36.5 (28.6-45.0) | 31.9 (21.3-47.1) | .001 |
| Bilirubin, µmol/L | 16.2 (2.0-341.1) | 40.6 (6.9-652.3) | .001 |
| Cholesterol, mmol/L | 4.49 (1.88-8.97) [n = 40] | 3.78 (1.14-16.44) [n = 24] | .560 |
| Triglyceride, mmol/L | 2.75 (1.29-9.89) [n = 40] | 2.50 (0.83-11.32) [n = 24] | .501 |
Laboratory data proximate to the time of ICH diagnosis are reported. AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CML , chronic myelogenous leukemia; DIC, disseminated intravascular coagulation; HLA, human leukocyte antigen; MDS, myelodysplastic syndrome; PB, peripheral blood; PLT, platelet; PT, prothrombin time; RBC, red blood cell; TMA, thrombotic microangiopathy.
For continuous variables, median and range are displayed, and the nonparametric Mann-Whitney test was used for calculating the P value. For categorical variables, number and percentage of total patients are displayed, and the χ2 test was used for significance calculation.
Others include lymphoma, acute mixed-lineage leukemia, lymphoma, chronic lymphocytic leukemia, and Epstein-Barr virus–associated hemophagocytic lymphohistiocytosis.
CNS diseases diagnosed before ICH diagnosis, including CNS leukemia, CNS infections, reversible posterior leukoencephalopathy syndrome, and ischemic stroke.